TZ9

TZ9 is a cell-permeable triazine compound that inhibits the human E2 ubiquitin-conjugating enzyme Rad6B. TZ9 selectively docks to the Rad6B catalytic site, inhibits Rad6B-induced histone H2A ubiquitination, downregulates intracellular beta-catenin, induces G2/M arrest and apoptosis, and inhibits proliferation and migration of metastatic human breast cancer cells (IC50 = 6 µM).Formal Name: 4-amino-6-(phenylamino)-2-(4-nitrobenzoate)-1,3,5-triazine-2-methanol. CAS Number: 1002789-86-7. Molecular Formula: C17H14N6O4. Formula Weight: 366.3. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 30 mg/ml, DMSO: 30 mg/ml, DMSO:PBS(pH 7.2) (1:2): 0.3 mg/ml. lambdamax: 209, 260 nm. SMILES: NC1=NC(COC(C2=CC=C([N+]([O-])=O)C=C2)=O)=NC(NC3=CC=CC=C3)=N1. InChi Code: InChI=1S/C17H14N6O4/c18-16-20-14(21-17(22-16)19-12-4-2-1-3-5-12)10-27-15(24)11-6-8-13(9-7-11)23(25)26/h1-9H,10H2,(H3,18,19,20,21,22). InChi Key: RRRDZFQRNJTKHL-UHFFFAOYSA-N.